Trials / Unknown
UnknownNCT03162432
High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Boston Children's Hospital · Academic / Other
- Sex
- All
- Age
- 7 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study will be to assess the safety and efficacy of high-dose interval Vitamin D3 therapy in children and young adults with Inflammatory Bowel Disease being treated with serial Remicade infusions.
Detailed description
Study subjects will receiving 50,000 units of Vitamin D3 if they receive Remicade infusions every 4-6 weeks. Study subjects will receiving 100,000 units of Vitamin D3 if they receive Remicade infusions every 6-8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vitamin D3 | Oral Vitamin D3 therapy. |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2017-05-22
- Last updated
- 2023-10-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03162432. Inclusion in this directory is not an endorsement.